Reach Us +1-504-608-2390
Discovery Of A Small Molecule Inhibitor Of Burton?s Tyrosine Kinase (BTK) For Autoimmune Diseases | 19557
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Discovery of a small molecule inhibitor of Burton?s Tyrosine Kinase (BTK) for autoimmune diseases

3rd International Conference and Exhibition on Clinical & Cellular Immunology

Loui Madakamutil

ScientificTracks Abstracts: J Clin Cell Immunol

DOI: 10.4172/2155-9899.S1.017

Takeda California utilized a structure based drug discovery approach to identify novel small molecule inhibitor of BTK. This talk will highlight the potential for the BTK small molecule inhibitor to control B cell and Fc receptor mediated immune pathology. Compound 9, the lead candidate was evaluated in vitro for its effect on B cell receptor (BCR) and Fc receptor mediated cellular function. Further compound 9 was tested for in vivo therapeutic effects in the rodent models of CIA and in the anti-GBM induced kidney damage model. These studies revealed that BTK is a viable target for identifying novel approaches to treat several autoimmune diseases that are mediated with B cell and Fc receptor diseases including rheumatoid arthritis and immune complex mediated kidney damage.
Loui Madakamutil has completed his PhD from Mumbai University and Postdoctoral studies from La Jolla Institute for Allergy and Immunology, San Diego. He is the Director and site head of Immunology Drug Discovery Unit Takeda California. He is an immunologist with more than 14 years of expertise in all aspects of small molecule and biological drug discovery process from hit to lead and first in human studies.
Relevant Topics